CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- PositionCurrent ratio is 14.67×, higher than 95% of its Medical Devices peers (median 3.87×)
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
3.14BCNY469.21M · vs all stocks (USD)
Revenue (TTM)
317.79MCNY47.42M · vs all stocks (USD)
Profit Margin
-8.13%vs Medical Devices peers
Beta
0.2140xvs all stocks
52-Week Change
-25.32%vs all stocks
Market Capitalization
3.14BCNY469.21M · vs all stocks (USD)
Enterprise Value
2.26BCNY337.69M · vs all stocks (USD)
Forward P/E
23.12xvs Medical Devices peers
Price to Sales (TTM)
9.89xvs Medical Devices peers
Price to Book (MRQ)
1.92xvs Medical Devices peers
Enterprise to Revenue
7.12xvs Medical Devices peers
Gross Margin
43.49%vs Medical Devices peers
Profit Margin
-8.13%vs Medical Devices peers
Operating Margin
-10.44%vs Medical Devices peers
Return on Assets (TTM)
-1.28%vs Medical Devices peers
Return on Equity (TTM)
-1.63%vs Medical Devices peers
Revenue (TTM)
317.79MCNY47.42M · vs all stocks (USD)
Revenue per Share (TTM)
0.5840CNYUpdated Sep 20, 2026Quarterly Revenue Growth
-0.10%vs Medical Devices peers
Gross Profit (TTM)
135.93MCNY20.28M · vs all stocks (USD)
EBITDA (TTM)
36.44MCNY5.44M · vs all stocks (USD)
Net Income (TTM)
-25.85MCNY-3.86M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
3.28%vs Medical Devices peers
Operating Cash Flow (TTM)
37.53MCNY5.60M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
35.33MCNY5.27M · vs all stocks (USD)
5-Year Average Dividend Yield
0.36%vs all stocks
Payout Ratio
0.00%vs Medical Devices peers
Minority Interest (Equity)
31.62MCNYFY2025 · Dec 31, 2025Revenue
326.31MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
162.83MCNYFY2025 · Dec 31, 2025Gross Profit
163.48MCNYFY2025 · Dec 31, 2025Operating Income
-23.52MCNY-3.51M · vs all stocks (USD)
Pre-tax Income
-17.54MCNYFY2025 · Dec 31, 2025Income Tax Expense
6.11MCNYFY2025 · Dec 31, 2025Net Income
-23.65MCNYFY2025 · Dec 31, 2025EBIT
-17.35MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
36.44MCNYFY2025 · Dec 31, 2025Research & Development
24.12MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
40.15MCNYFY2025 · Dec 31, 2025Other Operating Expenses
11.01MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
7.57MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
192.91KCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.0400CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.0400CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
574.58MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
574.58MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-23.65MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
665.72KCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-21.01MCNYFY2025 · Dec 31, 2025Free Cash Flow
-38.09MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
514.84MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-23.65MCNYFY2025 · Dec 31, 2025Other Non-cash Items
7.75MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
4.47MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-9.59MCNYFY2025 · Dec 31, 2025Capital Expenditures
-17.08MCNYFY2025 · Dec 31, 2025Purchase of Investments
-884.00MCNYFY2025 · Dec 31, 2025Sale of Investments
825.10MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-75.98MCNYFY2025 · Dec 31, 2025Other Financing Charges
-2.47MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-2.47MCNYFY2025 · Dec 31, 2025Shares Outstanding
544.01MSharesUpdated Sep 20, 2026Float Shares
290.74MSharesUpdated Sep 20, 2026% Held by Insiders
49.66%vs all stocks
% Held by Institutions
0.63%vs all stocks
Total Cash (MRQ)
915.94MCNY136.68M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.68CNYUpdated Sep 20, 2026Total Debt (MRQ)
2.70MCNY402.60K · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0016xvs Medical Devices peers
Current Ratio (MRQ)
14.67xvs Medical Devices peers
Book Value per Share (MRQ)
3.01CNYUpdated Sep 20, 2026Total Assets
1.78BCNY265.04M · vs all stocks (USD)
Total Current Assets
1.10BCNYFY2025 · Dec 31, 2025Total Liabilities
105.46MCNYFY2025 · Dec 31, 2025Total Non-current Assets
674.14MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
18.73MCNYFY2025 · Dec 31, 2025Total Current Liabilities
86.73MCNYFY2025 · Dec 31, 2025Cash
566.02MCNYFY2025 · Dec 31, 2025Cash Equivalents
1.10KCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
566.02MCNYFY2025 · Dec 31, 2025Other Short-term Investments
336.75MCNYFY2025 · Dec 31, 2025Accounts Receivable
85.87MCNYFY2025 · Dec 31, 2025Inventory
88.72MCNYFY2025 · Dec 31, 2025Accounts Payable
20.72MCNYFY2025 · Dec 31, 2025Short-term Debt
3.04MCNYFY2025 · Dec 31, 2025Other Current Liabilities
1.92MCNYFY2025 · Dec 31, 2025Long-term Debt
1.16MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
664.65KCNYFY2025 · Dec 31, 2025Common Stock (Book)
544.01MCNYFY2025 · Dec 31, 2025Retained Earnings
409.41MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.67BCNY249.31M · vs all stocks (USD)
52-Week Low
5.19CNYUpdated Sep 20, 202652-Week High
10.41CNYUpdated Sep 20, 202652-Week Change
-25.32%vs all stocks
Beta
0.2140xvs all stocks
50-Day MA
5.77CNYUpdated Sep 20, 2026200-Day MA
6.44CNYUpdated Sep 20, 2026Avg 10-Day Volume
4.60MSharesUpdated Sep 20, 2026Avg 30-Day Volume
6.41MSharesUpdated Sep 20, 2026Diluted EPS (TTM)
-0.0500CNYUpdated Sep 20, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Liquidity Ratios Elevated
It can cover near-term bills from cash alone, not just from inventory.
Reads
Low-Leverage Liquidity Configuration
Cash on hand covers most or all of its debt, and its equity share of assets is high for its industry.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Current ratio is 14.67×, higher than 95% of its Medical Devices peers (median 3.87×)Significant
Current ratio: 14.67Industry median: 3.87Industry P95: 12.55Peers compared: 102
Debt-to-equity is 0×, lower than 95% of its Medical Devices peers (median 0.11×)Notable
Debt-to-equity: 0.00Industry median: 0.11Industry P5: 0.00Peers compared: 102
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.43Profit Margin: -0.08
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Avacta Group Plc
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Pku Healthcare Corporation Limited
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Haisen Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Contineum Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Jenscare Scientific Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
908 Devices Inc.
Tier 1ProductionApproval-Gated PipelineRule
Yungshin Global Holding Corp.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Hyundai Bioscience Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Blau Farmacêutica S.A.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Beijing Kawin Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
Lafang China Co., Ltd.
2 interpretationsLiquidity Ratios ElevatedLow-Leverage Liquidity Configuration
Bitmine Immersion Technologies Inc.
2 interpretationsLiquidity Ratios ElevatedLow-Leverage Liquidity Configuration
Huabao Flavours & Fragrances Co., Ltd.
2 interpretationsLiquidity Ratios ElevatedLow-Leverage Liquidity Configuration